Enasidenib a key breakthrough in AML treatment in 2025

Enasidenib, trade nameIDHIFA, is an oral targeted drug developed specifically for the treatment of adult acute myeloid leukemia (AML) patients who carry isocitrate dehydrogenase 2 (IDH2) gene mutations. It was jointly developed by Agios Pharmaceuticals and Celgene and has been approved by the US FDA for marketing. Different from traditional chemotherapy, ensidipine represents a precise direction for AML treatment. It reverses tumor cell differentiation disorders by specifically inhibiting the activity of mutated IDH2 enzyme, allowing leukemia cells to mature again, thereby inhibiting the progression of cancer.

In the global oncology drug landscape in 2025, targeted therapy is becoming mainstream, and ensidipine is considered a "turning point" drug for patients with IDH-mutated AML. Since about 8%-12% of AML patients carry IDH2 mutations, this group of people has a low response rate to conventional chemotherapy and a high relapse rate. The emergence of ensidipine has brought new possibilities for long-term remission for these patients. Overseas experts pointed out that compared with traditional regimens, it can not only prolong patient survival, but also significantly improve the quality of life. Its tolerability is better than that of most cytotoxic drugs. This feature gives it a unique advantage in the era of precision medicine.

It is worth noting that ensidipine uses a small molecule targeting mechanism to block the metabolic abnormalities caused by mutationIDH2, reduce the accumulation of 2-hydroxyglutarate (2-HG), a key carcinogenic metabolite, and thereby restore normal cell differentiation. The innovative significance of this mechanism is that it does not "kill" cancer cells, but "corrects" their metabolic errors so that they can move toward differentiation and maturity again. Because of this, ensidipine is known as one of the representative drugs of "differentiation therapy".

Overseas, ensidipine has been included in clinical guidelines of many countries since its launch, and is often used in combination with other targeted drugs or low-intensity chemotherapy for second-line and maintenance treatment of relapsed or refractory AML patients. The drug has shown good disease control rate and sustained remission ability in patients with IDH2 mutations, and has become a key drug for hematology and oncology experts.

Reference materials:https://www.idhifa.com/